Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis

Featuring an interview from Dr John Strickler, including the following topics:

• Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00)
• Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09)
• Tumor-informed MRD assays under clinical development (20:36)
• Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19)
• Case: A man in his late 50s with resected Stage IIA colon cancer (30:06)
• Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57)
• MRD as a future clinical trial endpoint for solid tumors; increasing incidence of colorectal cancer in younger people (40:24)
• Antibody-drug conjugates in the treatment of colorectal cancer (45:13)
• Perspectives on promising areas of clinical research in colorectal cancer (48:23)

CME information and select publications